Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, R&D spend, and cash-runway figures in Arcutis Biotherapeutics (ARQT) SEC documents can stretch across hundreds of pages. If you need to know how ZORYVE sales offset development costs or where the next PDE4 program stands, wading through every quarterly update is time-consuming and complex.
Stock Titan solves this problem with AI-powered summaries that turn raw disclosures into plain-English takeaways. Whether you are searching for “Arcutis quarterly earnings report 10-Q filing,” want “Arcutis insider trading Form 4 transactions,” or need an “Arcutis proxy statement executive compensation” breakdown, our engine surfaces the exact paragraph in seconds. Real-time alerts appear the moment an “Arcutis Form 4 insider transactions real-time” notice hits EDGAR, while cross-links let you compare each metric historically for quick “Arcutis earnings report filing analysis.”
Dive deeper without the jargon: jump straight to liquidity tables in the “Arcutis annual report 10-K simplified,” scan risk-factor changes, or review pivotal Phase 3 data inside an “Arcutis 8-K material events explained” filing. Many professionals rely on us for “understanding Arcutis SEC documents with AI” because our platform highlights option-exercise patterns under “Arcutis executive stock transactions Form 4,” flags non-recurring charges, and maps clinical timelines to projected market launches. With comprehensive coverage of every 10-K, 10-Q, 8-K, S-1, and Form 4, plus clear explanations, complex immuno-dermatology disclosures finally make sense.
Arcutis Biotherapeutics, Inc. (ARQT) – Form 144 filing: Insider Masaru Matsuda filed notice to dispose of up to 6,330 common shares through Merrill (Columbus, OH) on or after 08/04/2025. At the most recent market price, the proposed sale is valued at $90,687. The shares originate from a restricted-stock vesting on 08/01/2025. Arcutis has 11.92 million shares outstanding, so the sale equals roughly 0.05 % of shares outstanding.
During the past three months Matsuda already sold 6,830 shares for gross proceeds of $101,261 (5/02 & 5/28 2025). Form 144 is a notice only; execution is not assured. By signing, the filer affirms no undisclosed material adverse information exists. No other operational or financial metrics were disclosed.
Arcutis Biotherapeutics, Inc. (ARQT) filed a Form 144 indicating a planned disposition of 89 common shares (≈ $1,255 market value) through Merrill Lynch on or after 4 Aug 2025. The shares represent <0.0001% of the company’s 119.2 million shares outstanding and were acquired via a restricted-stock vest on 1 Aug 2024.
The same insider, Latha Vairavan, previously sold an identical block of 89 shares for $1,329 on 5 May 2025. No other sales or material considerations are disclosed. Form 144 requires the filer to state that they possess no undisclosed adverse information and to acknowledge potential penalties for misstatements.
Investment-relevance: The proposed sale is de minimis and does not alter ownership structure, liquidity, or strategic outlook. It is therefore unlikely to affect ARQT’s valuation or trading dynamics.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
